Liraglutide, a Glucagon-Like-Peptide-1 (GLP-1) analogue, was linked to enhancements in weight, metabolic parameters, and high quality of life in sufferers with genetic obesity, based on findings offered on the Endocrine Society’s Annual Assembly (ENDO 2021).
“In these sufferers, therapy-resistant weight problems is usually noticed regardless of intensive life-style therapy,” the investigators famous. “Furthermore, it’s nonetheless unclear whether or not bariatric surgical procedure is much less profitable in genetic weight problems.”
Led by Mila Sofie Welling, MD, Erasmus College Medical Middle, the investigative workforce evaluated the security and efficacy of the GLP-1 analogue plus life-style therapy in 4 sufferers who have been both overweight or obese as a result of a genetic trigger.
As such, 2 sufferers had a heterozygous pathogenic melanocortin 4 recepter variant and a couple of had 16p11.2 deletion syndrome. Ages ranged from 21-32 years of age, with BMI starting from 28.1 kg/m2 – 55 kgkg/m2.
All sufferers have been handled day by day with 3.0 mg of liraglutide.
“At finish of follow-up, ranging between 33 weeks and 12 years, a imply change in BMI and waist circumference was noticed of -5.7 ± 3.8 kg/m2 and -15.2 ± 21.1 cm, respectively,” the investigators reported.
Additionally they reported higher high quality of life and metabolic parameters in all sufferers in addition to improved satiety in 3 sufferers. Nevertheless, there was no noticed impact of liraglutide on resting power expenditure.
Moreover, gentle however temporary unintended effects—reminiscent of reminiscent of nausea and abdomen ache—occurred in 2 sufferers.
“Our findings counsel that GLP-1 analogue therapy is likely to be an efficient therapy possibility, along with a wholesome life-style, for sufferers with genetic weight problems,” Welling and Colleagues wrote.
Pediatric Sufferers, Different Makes use of of Liraglutide
Liraglutide has had a comparatively longer historical past to be used in diabetes therapy.
Earlier analysis has proven liraglutide as add-on remedy to be efficacious in bettering glycemic management in youngsters and adolescents (along with adults) with kind 2 diabetes.
Results published in 2019 indicated that the GLP-1 receptor agonist plus metaformin was related to larger decreases in HbA1c stage—in contrast with imply will increase in youngsters who obtained metaformin plus placebo.
Additional, 63.7% of sufferers receiving liraglutide achieved a glycated hemoglobin stage of seven.0% by the top of the trial, versus solely 36.5% within the placebo group.
The results of the drug on pediatric weight reduction have but to be ascertained.
Liralgutide, offered underneath model identify Victoza, is at present accepted by the US Meals and Drug Administration (FDA) for the therapy of kind 2 diabetes in each adults and children 10 years and older.
The FDA additionally approved it for danger discount of coronary heart assault, stroke, and cardiovascular dying, in sufferers with kind 2 diabetes.
The research, “Effects of Glucagon-Like-Peptide-1 Analogue Treatment in Genetic Obesity,” was offered at ENDO 2021.